IL1B and COVID-19: JAK2 inhibitor Fedratinib has been proved to inhibit the production of several Th17 cytokines, including IL-6, IL-17, IL-21, IL-22, IL-1β, and TNF-α, thereby preventing Th17-related cytokine storm in COVID-19 patients (94).